# Development of national biobank for lysosomal storage disorders in India- a step towards advancing research and precision medicine

## TL;DR

India's first national biobank for lysosomal storage disorders has been established, offering a centralized resource for research and precision medicine.

## Contribution

The creation of the first government-supported national LSDs biobank in India, with a focus on clinical-genomic data and sample collection.

## Key findings

- The biobank includes 530 patients across 8 LSD subgroups and 27 disorders, with samples from 15 Indian states.
- Common genetic variants like c.1448T > C in GBA1 and c.1385C > T in HEXA were identified, along with novel mutations.
- The biobank provides a scalable model for rare disease research in low- and middle-income countries.

## Abstract

Lysosomal storage disorders (LSDs) are a diverse group of over 70 rare, inherited metabolic conditions that present significant diagnostic and therapeutic challenges, especially in genetically diverse and resource-limited settings like India. To address the lack of a centralized clinical and genomic data registry for LSDs, we established the first government-supported national LSDs biobank in India. This study describes the infrastructure, sample collection, storage procedures, ethical framework, and expected impact of the biobank on research, diagnostics, and patient care.

The study includes biological samples and clinical-genetic data from 530 patients, (526 unrelated individuals and 2 sibling pairs), over a 17-year period (2008–2025). Biological samples including genomic DNA from blood, plasma, and urine precipitate were processed for enzyme and genetic investigations. A centralized webpage has been established to manage the biological sample data including clinical, enzyme and genetic data.

The LSD biobank cohort encompasses 8 LSD subgroups across 27 disorders, with the most common being Gaucher disease (n = 70), Tay-Sachs disease (n = 62), Mucolipidosis (ML) II/III (n = 44), and Morquio-A (n = 40). Samples originated from 15 Indian states, with a predominance of pediatric cases. Detailed phenotypic, enzymatic, and genomic profiles were generated. Enzyme assays confirmed markedly reduced activity in most cases, with variable residual activity noted in few LSDs. Genetic analyses using Sanger sequencing, PCR-RFLP, targeted gene panel sequencing, and/ or whole exome sequencing detected causative variants. Notably, c.1469T > C in the IDUA gene (29.4% in Hurler disease), c.230 C > G in the GALNS gene (22.5% in Morquio-A disease), c.1448T > C in the GBA1 gene (56% in Gaucher disease), and c.1385 C > T and c.964G > T in the HEXA gene (11.3% and 8.1% respectively in Tay-Sachs disease) were the most common variants. Several novel, private mutations were also identified, broadening the mutational landscape of LSDs.

The present study represents a scalable model for rare disease research in low- and middle-income countries. This resource lays the foundation for genotype–phenotype correlation studies, natural history analyses, and future precision medicine strategies tailored to the Indian population.

The online version contains supplementary material available at 10.1186/s13023-026-04195-8.